Barf Tjeerd, Lehmann Fredrik, Hammer Kristin, Haile Saba, Axen Eva, Medina Carmen, Uppenberg Jonas, Svensson Stefan, Rondahl Lena, Lundbäck Thomas
Department of Medicinal Chemistry, Biovitrum AB, Research, 112 76 Stockholm, Sweden.
Bioorg Med Chem Lett. 2009 Mar 15;19(6):1745-8. doi: 10.1016/j.bmcl.2009.01.084. Epub 2009 Jan 30.
Small molecule inhibitors of adipocyte fatty-acid binding protein (A-FABP) have gained renewed interest following the recent publication of pharmacologically beneficial effects of such inhibitors. Despite the potential utility of selective A-FABP inhibitors within the fields of metabolic disease, inflammation and atherosclerosis, there are few examples of useful A-FABP inhibitors in the public domain. Herein, we describe the optimization of N-benzyl-tetrahydrocarbazole derivatives through the use of co-crystal structure guided medicinal chemistry efforts. This led to the identification of a potent and selective class of A-FABP inhibitors as illustrated by N-benzyl-hexahydrocyclohepta[b]indole 30.
在最近发表了脂肪细胞脂肪酸结合蛋白（A-FABP）小分子抑制剂的药理有益作用后，这类抑制剂再次引起了人们的关注。尽管选择性A-FABP抑制剂在代谢疾病、炎症和动脉粥样硬化领域具有潜在用途，但公开领域中有用的A-FABP抑制剂实例却很少。在此，我们通过使用共晶体结构导向的药物化学方法描述了N-苄基-四氢咔唑衍生物的优化。这导致鉴定出一类有效的选择性A-FABP抑制剂，如N-苄基-六氢环庚并[b]吲哚30所示。
